Results 131 to 140 of about 2,404 (154)

Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland. [PDF]

open access: yesAppl Health Econ Health Policy
Bainbridge J   +5 more
europepmc   +1 more source

Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey. [PDF]

open access: yesPLoS One
Di Chiara C   +16 more
europepmc   +1 more source

Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network. [PDF]

open access: yesLancet Reg Health West Pac
Wadia U   +15 more
europepmc   +1 more source

Maternal Immunization Against Respiratory Syncytial Virus: An Updated WAidid Consensus Document on Evidence, Implementation, and Public Health Priorities. [PDF]

open access: yesVaccines (Basel)
Esposito S   +10 more
europepmc   +1 more source

Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia. [PDF]

open access: yesInfect Dis Ther
Carrasquilla-Sotomayor M   +7 more
europepmc   +1 more source

Acute Respiratory Infections in Children: A Narrative Perspective on Integrated Primary-Hospital Care in Italy. [PDF]

open access: yesChildren (Basel)
Indolfi C   +5 more
europepmc   +1 more source

Impact of Universal Nirsevimab Immunoprophylaxis on RSV-Related Hospitalizations in Infants: A Two-Season Multicenter Study in Northern Italy. [PDF]

open access: yesPathogens
Gianotto NR   +11 more
europepmc   +1 more source

Cell culture medium influences RSV G protein glycosylation and recognition by monoclonal antibodies. [PDF]

open access: yesVirol J
Engling N   +6 more
europepmc   +1 more source

Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus. [PDF]

open access: yesInfect Dis Ther
Alharbi AS   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy